Mechanisms of dual pathway inhibition with low-dose DOACs and antiplatelet therapy mediating thrombin-derived mechanisms of both VTE and ATE in medically ill patients.

ADP, adenosine diphosphate; COX, cyclooxygenase; FIX, factor XI inhibitors; GP, glycoprotein; P2Y1, platelet ADP P2Y1 receptor; TXA₂, thromboxane A₂; VWF, von Willebrand factor. Reproduced with permission from Goldin et al.¹⁴